The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
HOME > April 22, 2025
Daily News
April 22, 2025
- New JPMA Task Force to Respond to ICH-GL and PMD Act Amendments
April 22, 2025
- JPMA to Investigate the Status of Application of Japanese PI Waiver
April 22, 2025
- LDP Tariff Task Force Broadly OKs First Proposal
April 22, 2025
- Pfizer to Donate RSV Jabs to 12 Municipalities in Noto Peninsula
April 22, 2025
- Ono Links Arms with Jorna on RNA Editing Therapeutics
April 22, 2025
- Novo Partners with Asahikawa City on Obesity Measures
April 22, 2025
- Enhertu Hits Mark in 1st Line Breast Cancer with PIII Trial Win
April 22, 2025
- Effexor Filed for Generalized Anxiety Disorder in Japan: Viatris
April 22, 2025
- GSK’s Blenrep, Moderna RSV Jab Edge Closer to Japan Approval with Panel OK
April 22, 2025
Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…